Bone Biologics and the University of California Los Angeles plan to begin their joint venture clinical trial testing the efficacy of their bone graft substitute treatment for spinal fusion, trauma, osteoporosis and other bone-related indications in 2023.
The trial, to be hosted in Australia, will evaluate if the duo's bone graft substitute, NB1, is suitable for use in humans, according to an Oct. 25 letter to Bone Biologic stockholders from Jeffrey Frelick, the company's CEO and president. A clinical trial testing the product in sheep found that the treatment "safely and effectively" promoted spinal fusion.
"We are optimistic that spinal fusion patients will benefit from our solution to the problem of hard-to-heal bones, and we are very excited about the potential to help these patients as we advance NB1 along the development pathway," he wrote in the letter, which was shared via an Oct. 25 news release. "We believe our effort will be well rewarded not only by patients, but also by caregivers and Bone Biologics stockholders."